Karolinska Development: Modus granted IND

Research Note

2018-11-07

10:52

Karolinska Development announced today that Modus Therapeutics has been granted Investigational New Drug (IND) status, paving the way for a phase I trial with a subcutaneous formulation of Sevuparin in the U.S. The announcement was in line with our expectations and will not affect our valuation of Karolinska Development.

AN

AH

Arvid Necander

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.